Hello –
What if you could use market volatility instead of fearing it?
Our new report, Unlock the Potential in Options Trading, shows you exactly how skilled traders do just that—leveraging hedging, strategic setups, and the “75% Solution” to capture profits while controlling risk.
Inside, you’ll learn:
- How a $1,000 Apple call outperformed a $12,500 stock position 6-to-1, turning an 8% move into a 50% gain
- How to apply the three-step “Chart, Choose, Time” setup to nail entries, target a 2:1 reward-to-risk, and let trades breathe
- How to use the “75% Solution” risk discipline to know precisely when to bank winners or cut losers
- How to select strikes, set expirations, and take profits through a real Tesla bull-call spread case study
- How to avoid common pitfalls like over-trading, emotion-driven decision making, and ignoring the tech tools that pros rely on
Whether you’re new to options or ready to tighten up your process, this concise PDF gives you the rules, examples, and checklists you need to trade with confidence.
👉 Download your complimentary Options Trading guide now.
No cost. No obligation. Just practical tactics you can put to work before the next market move.
See you inside,
Matthew Paulson
Founder & CEO, MarketBeat
P.S. Options aren’t just for Wall Street pros. Any investor can use them to seek income or protection. Grab the guide today and see how the right contract can power your next trade.
Monday’s Featured Content
Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus
Reported by Jessica Mitacek. Originally Published: 5/8/2026.
Key Points
- Following a settled legal dispute with Novo Nordisk, HIMS has transitioned from selling compounded weight-loss drugs to offering brand-name Wegovy and Ozempic.
- While the deal was finalized in March, investors are eager to see if this pivot will boost the top line or if the financial impact likely won’t be seen until Q2.
- Despite its recent rally, the stock remains highly volatile with short interest exceeding 35%.
- Special Report: Elon Musk already made me a “wealthy man”
Healthcare stocks have struggled in 2026. With a year-to-date (YTD) decline of about 6%, the sector has been the worst performer among all 11 S&P 500 sectors this year.
That weakness has been reflected in the YTD losses of some of Big Pharma’s biggest names, but it has also weighed on mid-cap stocks like telehealth platform Hims & Hers Health (NYSE: HIMS), which has fallen by more than 23% in 2026.
The $7 stock Nvidia needs to finish the job (Ad)
Jensen Huang stood in Las Vegas and laid out Nvidia’s vision for building the world’s first trillion-dollar robot. But there’s one thing Nvidia can’t do alone.
A virtually unknown $7 company holds the technology Nvidia needs to make that vision a reality. Analyst Michael Robinson – who called Nvidia at $0.80 and Bitcoin at $300 – has identified this stock as his next potential winner, with nearly 20 prior calls returning 1,000% or more.Click here to learn which $7 stock Nvidia needs right now
One day after a big announcement from the U.S. Food & Drug Administration (FDA) sent HIMS shares up nearly 4%, the stock gave back those gains on Thursday, falling by nearly 5% as traders locked in profits.
Even so, that wasn’t enough to derail the stock’s recent rally. HIMS has gained nearly 32% over the past month and around 77% since its 52-week low on Feb. 27. As the company prepares to report Q1 2026 earnings on May 11, here’s what investors should watch for.
Is the Novo Nordisk Partnership Already Paying Off?
Following a well-publicized legal disputeearlier this year with Denmark-based Novo Nordisk (NYSE: NVO)—the eighth largest publicly traded pharmaceutical company in the world with a market cap of more than $204 billion—it has been smooth sailing for Hims & Hers.
Since Novo Nordisk dropped its patent infringement lawsuit on March 9, HIMS has been on a tear. Not only did the Danish firm abandon its case, but it also reached a deal that allows Hims & Hers to sell Novo Nordisk’s brand-name Wegovy and Ozempic through its direct-to-consumer and virtual medical services platform.
As part of that deal, Hims & Hers agreed to stop advertising its compounded GLP-1 products, a move that could prove prescient given the FDA’s announcement that it is proposing semaglutide, tirzepatide, and liraglutide be excluded from its 503B bulks list.
Wall Street will be watching to see how that deal has affected Hims & Hers’ top line. Although the strategic shift was announced on March 9, Novo Nordisk’s GLP-1 products were not available for sale through the online platform until March 26. The quarter closed on March 31, so those gross sales may not appear on Hims & Hers’ income statement until Q2.
Will Hims & Hers Continue to Show Subscriber Growth?
The market will also be looking for confirmation that Hims & Hers’ total subscribers are holding above 2.5 million, if not steadily growing from there. That benchmark was reached near the end of 2025 and marked a more than 16% increase from the 2.2 million subscribers the company had at the end of 2024.
That growth appears sustainable after Hims & Hers ended 2023 with 1.5 million subscribers. But more important than the raw subscriber count is how the telehealth company generates 90% of its recurring revenue from its customer base.
Approximately 82% of its users remain on the platform for more than three months, and if Hims & Hers can show that trend is sustainable, it should bolster full-year guidance.
Meanwhile, analysts are expecting earnings per share (EPS) of around three to four cents, which would mark an estimated 90% year-over-year decline. That may already be priced in, given the stock’s YTD performance, but a miss could accelerate selling.
The same goes for quarterly revenue, which consensus forecasts put in the range of $616 million to $619 million. Wall Street is already bracing for a “reset quarter” after revenue growth slowed from nearly 111% in Q1 2025 to less than 29% in Q4, so any surprise to the upside could spur another leg higher in the current rally.
Analysts Are Taking a Wait-and-See Approach
Despite an average 12-month price target of nearly $32, which implies potential upside of around 24%, Wall Street remains cautious on the stock.
Of the 17 analysts currently covering HIMS, four rate it a Buy, 12 rate it a Hold, and just one rates it a Sell. Overall, the stock carries a consensus Hold rating.
Institutional ownership of nearly 64% falls within the typical range for mid-cap companies. Outflows of $1.62 billion have nearly caught up with inflows of $1.8 billion over the past 12 months after selling accelerated in Q4 2025. But that trend reversed in Q1, with institutional selling 88% lower than institutional buying.
With a high beta of 2.43, the inherently volatile stock is currently drawing heavy interest from bears. Concerningly, more than 35% of the float—or nearly 70 million shares of the almost 228 million shares outstanding—is currently shorted.
Still, strong earnings could shift sentiment and move the stock closer to the consensus analyst price target. Shareholders and prospective investors should mark their calendars for Monday, May 11, when Hims & Hers Health reports Q1 2026 results.
Thank you for subscribing to MarketBeat!
We empower individual investors to make better trading decisions by providing up-to-the-minute financial information and independent market analysis.
If you have questions or concerns about your account, please email our South Dakota based support team at contact@marketbeat.com.
If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribefrom these emails.
Copyright 2006-2026 MarketBeat Media, LLC. All rights reserved.
345 N Reid Pl., Sixth Floor, Sioux Falls, SD 57103. USA..
Market alerts, actionable tips, and timely insights to fuel your investment success.
RJ Hamster 